<code id='3AAF2F1D18'></code><style id='3AAF2F1D18'></style>
    • <acronym id='3AAF2F1D18'></acronym>
      <center id='3AAF2F1D18'><center id='3AAF2F1D18'><tfoot id='3AAF2F1D18'></tfoot></center><abbr id='3AAF2F1D18'><dir id='3AAF2F1D18'><tfoot id='3AAF2F1D18'></tfoot><noframes id='3AAF2F1D18'>

    • <optgroup id='3AAF2F1D18'><strike id='3AAF2F1D18'><sup id='3AAF2F1D18'></sup></strike><code id='3AAF2F1D18'></code></optgroup>
        1. <b id='3AAF2F1D18'><label id='3AAF2F1D18'><select id='3AAF2F1D18'><dt id='3AAF2F1D18'><span id='3AAF2F1D18'></span></dt></select></label></b><u id='3AAF2F1D18'></u>
          <i id='3AAF2F1D18'><strike id='3AAF2F1D18'><tt id='3AAF2F1D18'><pre id='3AAF2F1D18'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:focus    Page View:797

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In